Acasti Pharma Net Income vs. EBITDA

ACSTDelisted Stock  USD 3.37  0.01  0.30%   
Based on the key profitability measurements obtained from Acasti Pharma's financial statements, Acasti Pharma may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Acasti Pharma's ability to earn profits and add value for shareholders.
For Acasti Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Acasti Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Acasti Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Acasti Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Acasti Pharma over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Please note, there is a significant difference between Acasti Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Acasti Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acasti Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Acasti Pharma EBITDA vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Acasti Pharma's current stock value. Our valuation model uses many indicators to compare Acasti Pharma value to that of its competitors to determine the firm's financial worth.
Acasti Pharma is rated fifth in net income category among its peers. It is rated third in ebitda category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Acasti Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Acasti EBITDA vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Acasti Pharma

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(12.85 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Acasti Pharma

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(11.3 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Acasti EBITDA Comparison

Acasti Pharma is currently under evaluation in ebitda category among its peers.

Acasti Pharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Acasti Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Acasti Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Acasti Pharma's change in net profit over the period of time. It can combine multiple indicators of Acasti Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.

Acasti Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Acasti Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Acasti Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Acasti Pharma's important profitability drivers and their relationship over time.

Use Acasti Pharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acasti Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acasti Pharma will appreciate offsetting losses from the drop in the long position's value.

Acasti Pharma Pair Trading

Acasti Pharma Pair Trading Analysis

The ability to find closely correlated positions to Acasti Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acasti Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acasti Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acasti Pharma to buy it.
The correlation of Acasti Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acasti Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acasti Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acasti Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Acasti Pharma position

In addition to having Acasti Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Artificial Intelligence Thematic Idea Now

Artificial Intelligence
Artificial Intelligence Theme
Technology companies, funds, and ETFs across multiple industries that are involved in research or development in the field of reasoning, learning, natural language processing and perception as well as its application to science and commerce. This theme may also include entities involved in cybernetics and cognitive brain simulation field. The Artificial Intelligence theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Artificial Intelligence Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Other Consideration for investing in Acasti Stock

If you are still planning to invest in Acasti Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acasti Pharma's history and understand the potential risks before investing.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Share Portfolio
Track or share privately all of your investments from the convenience of any device